MSA Capital
China GPs seek global angles as domestic deployment slows - AVCJ Forum
Global expansion remains a bright spot in China’s investment landscape as private equity firms slow deployment domestically in favour of supporting China-related entrepreneurs or business concepts in other markets, the AVCJ Private Equity & Venture...
China's DP Technology raises $97m
China’s DP Technology, touted as a pioneer in the use of artificial intelligence (AI) for scientific research, has raised a CNY 700m (USD 97m) round featuring Loyal Valley Capital.
SDIC leads $97m Series A for China's Pyrotech Therapeutics
China-based Pyrotech Therapeutics, which develops treatments for inflammation and tumours, has raised a Series A of CNY 700m (USD 97m) led by state-owned investor SDIC Venture Capital.
Ex-Eaton Asia head targets asset management, GP stakes
Chris Lerner, formerly of Eaton Partners and MSA Capital, has established an asset management operation that will ultimately raise an Asian fund-of-funds and teamed up with US-based Bonaccord Capital Partners to expand its GP stakes business into the...
Gulf gambit: Asia GPs court Middle East LPs
As the Middle East becomes a focal point for private equity fundraising globally, Asia-based managers hope that macro trends work in their favour. Being the right size and the right strategic fit also helps
China fundraising: Onshore vs offshore
Raising capital for China strategies is difficult right now, regardless of currency, but are geopolitical forces enabling the rise of renminbi-denominated funds at the expense of the US dollar?
VC-backed Asia streaming business agrees SPAC merger
Asia Innovations Group (ASIG), a social media, gaming, and e-commerce business best known for the Uplive streaming platform, has agreed to merge with a US-listed special purpose acquisition company (SPAC) at an equity valuation of USD 2.5bn.
Matrix leads Series B for China's SpeedBot Robotics
Matrix Partners has led a CNY 300m (USD 44m) Series B round for SpeedBot Robotics, a China-based start-up specialising in vision-guided intelligent robotics.
Profile: MSA Capital’s Jenny Zeng
Having participated in Chinese private equity as GP, LP, advisor, and industry association executive, Jenny Zeng has clear ideas as to what makes a good founder. These are being put into practice at MSA Capital
China biotech: End of the boom
PE investment in China biotech has collapsed amid failed IPO processes and disputed valuations. Pockets of activity remain, though questions around commercialisation have yet to be answered
China RNA vaccine developer raises $42m
Therorna, a China-based biotech company specializing in vaccines and drugs based on circular RNA technology, has raised USD 42m in Series A funding.
China outbound: Organic options
Tough domestic competition is encouraging Chinese tech start-ups to expand overseas – often organically, earlier in their lifecycles than before, and despite regulatory concerns